Combination of HER2-Targeted Antibodies (Trastuzumab plus Pertuzumab) is Effective Against HER2 Amplified Ovarian Cancer Xenograft Models

S. P. Langdon, A. H. Sims, D. J. Harrison

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)25-25
Number of pages1
JournalThe Journal of Pathology
Publication statusPublished - Sep 2013
Event7th Joint Meeting of the British-Division of the International-Academy-of-Pathology and the Pathological-Society-of-Great-Britain-and-Ireland - Edinburgh, United Kingdom
Duration: 18 Jun 201321 Jun 2013

Cite this